Prentice Wealth Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Prentice Wealth Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-120	Closed	-$2K	–	339
2021 Q3	$2K	Hold	120	–	–	﹤0.01%	306
2021 Q2	$1K	Hold	120	–	–	﹤0.01%	338
2021 Q1	$1K	Buy	+120	New	+$1.48K	﹤0.01%	333

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Prentice Wealth Management's TRIL Position: Q4 2021 in Review

Prentice Wealth Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 120 shares — an estimated $2K sold.

Prentice Wealth Management first reported a position in TRIL in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Prentice Wealth Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Prentice Wealth Management sold 120 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2K.
Prentice Wealth Management first reported a position in Trillium Therapeutics Inc. in Q1 2021 and held it in 3 quarters.
Prentice Wealth Management's Trillium Therapeutics Inc. position peaked at $2K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Prentice Wealth Management's 13F filing for Q4 2021, filed 31 Oct 2022.